Peptide Center / Retatrutide
Positive Phase 3 topline data · not approvedRetatrutide: evidence, status & safety
Retatrutide is an investigational triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. Multiple Phase 3 studies have reported positive topline results, but FDA has not approved it for any condition.
What patients should know first
| Commonly discussed for | Potential next-generation weight treatment, sometimes called “triple-G” because it activates GIP, GLP-1 and glucagon receptors. |
| TRIUMPH-1 | Lilly reported mean weight changes at 80 weeks of −19.0%, −25.9% and −28.3% for 4, 9 and 12 mg, versus −2.2% with placebo, using an efficacy estimand. These are sponsor-reported topline data pending full peer-reviewed publication and FDA review. |
| TRIUMPH-2 and -3 | On July 23, Lilly reported up to −20.8% mean weight change in adults with obesity/overweight and type 2 diabetes and up to −22.6% in adults with severe obesity and established cardiovascular disease. The cardiovascular event analyses were imprecise and did not establish cardiovascular benefit. |
| Approval boundary | There is no FDA-approved retatrutide product as of July 31, 2026. FDA says retatrutide cannot be used in compounding under federal law and warns against products sold directly to consumers as compounded or “research” retatrutide. |
| What may happen next | Lilly states that it plans to submit a Biologics License Application in Q1 2027. A planned submission is not a filing, review completion, approval date or guarantee. |
| Safety context | Gastrointestinal events, dysesthesia and treatment discontinuations increased in some dose groups. Long-term benefit-risk assessment and manufacturing review remain incomplete until FDA reviews a submitted application. |
Where retatrutide stands today
This visual shows regulatory progression, not probability of approval.
Status checked September 3, 2026. Bar length is a design aid for process stage; it is not a forecast, score or clinical comparison.
Do not confuse a molecule with a verified medication
The name of an active ingredient does not verify the product in a vial. FDA approval, when it exists, applies to a specific product and indication. A compounded version is not FDA-approved, and a research-labeled product is not approved for human use.
Clinical supervision should include diagnosis, contraindication and interaction review, realistic outcome discussion, a valid prescription, traceable sourcing and follow-up. It cannot make an anonymous or counterfeit product safe.
Questions to ask
- Is there an FDA-approved product for my exact condition?
- What human outcome—not only biomarker—supports this use?
- What are the important contraindications and stopping rules?
- Which licensed pharmacy will dispense the prescription?
- How will response and adverse effects be monitored?
Know the status.
Verify the source.
This guide is educational and cannot determine whether Retatrutide is appropriate for you.